Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)
Switching COPD Patients From Spiriva® HandiHaler® Maintenance Therapy to Spiriva® Respimat®: a Non-Interventional Real-world clinicAl ouTcome assEssment: NIS PIRATE
Sponsor: Boehringer Ingelheim
Terminated
Insufficient recruitment
Other terminated trials from Boehringer Ingelheim
Other Pulmonary Disease, Chronic Obstructive trials with similar outcome
Listed as NCT05362487, this observational or N/A phase trial focuses on Pulmonary Disease, Chronic Obstructive and remains terminated or withdrawn. Sponsored by Boehringer Ingelheim, it has been updated 12 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Mar 2025 — Present [monthly]
Terminated
-
Sep 2024 — Mar 2025 [monthly]
Terminated
-
Aug 2024 — Sep 2024 [monthly]
Terminated
-
Jul 2024 — Aug 2024 [monthly]
Terminated
-
Mar 2023 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .